JP7090151B2 - 特定のｖｍａｔ２インヒビターを投与するための方法 - Google Patents

特定のｖｍａｔ２インヒビターを投与するための方法 Download PDF

Info

Publication number
JP7090151B2
JP7090151B2 JP2020520311A JP2020520311A JP7090151B2 JP 7090151 B2 JP7090151 B2 JP 7090151B2 JP 2020520311 A JP2020520311 A JP 2020520311A JP 2020520311 A JP2020520311 A JP 2020520311A JP 7090151 B2 JP7090151 B2 JP 7090151B2
Authority
JP
Japan
Prior art keywords
patient
vmat2
item
disorder
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536905A5 (enExample
JP2020536905A (ja
Inventor
クリストファー エフ． オブライエン，
ヘイグ ピー． ボゼジアン，
Original Assignee
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62978647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7090151(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューロクライン バイオサイエンシーズ，インコーポレイテッド filed Critical ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Publication of JP2020536905A publication Critical patent/JP2020536905A/ja
Publication of JP2020536905A5 publication Critical patent/JP2020536905A5/ja
Priority to JP2022008580A priority Critical patent/JP2022040408A/ja
Application granted granted Critical
Publication of JP7090151B2 publication Critical patent/JP7090151B2/ja
Priority to JP2023149999A priority patent/JP2023161033A/ja
Priority to JP2025126262A priority patent/JP2025146959A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
JP2020520311A 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法 Active JP7090151B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022008580A JP2022040408A (ja) 2017-01-27 2022-01-24 特定のｖｍａｔ２インヒビターを投与するための方法
JP2023149999A JP2023161033A (ja) 2017-01-27 2023-09-15 特定のｖｍａｔ２インヒビターを投与するための方法
JP2025126262A JP2025146959A (ja) 2017-01-27 2025-07-29 特定のｖｍａｔ２インヒビターを投与するための方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451605P 2017-01-27 2017-01-27
PCT/US2017/055907 WO2018140093A1 (en) 2017-01-27 2017-10-10 Methods for the administration of certain vmat2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022008580A Division JP2022040408A (ja) 2017-01-27 2022-01-24 特定のｖｍａｔ２インヒビターを投与するための方法

Publications (3)

Publication Number Publication Date
JP2020536905A JP2020536905A (ja) 2020-12-17
JP2020536905A5 JP2020536905A5 (enExample) 2021-02-04
JP7090151B2 true JP7090151B2 (ja) 2022-06-23

Family

ID=62978647

Family Applications (16)

Application Number Title Priority Date Filing Date
JP2020520311A Active JP7090151B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2019540568A Active JP7199360B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2019540570A Active JP7199361B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2019540557A Active JP7199359B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2019540650A Active JP7107950B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022008580A Withdrawn JP2022040408A (ja) 2017-01-27 2022-01-24 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022113075A Withdrawn JP2022137219A (ja) 2017-01-27 2022-07-14 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022160177A Withdrawn JP2022174343A (ja) 2017-01-27 2022-10-04 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022160833A Withdrawn JP2022174345A (ja) 2017-01-27 2022-10-05 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022160831A Withdrawn JP2022174344A (ja) 2017-01-27 2022-10-05 特定のｖｍａｔ２インヒビターを投与するための方法
JP2023149999A Pending JP2023161033A (ja) 2017-01-27 2023-09-15 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024092155A Pending JP2024107169A (ja) 2017-01-27 2024-06-06 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024092148A Pending JP2024107167A (ja) 2017-01-27 2024-06-06 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024092152A Pending JP2024107168A (ja) 2017-01-27 2024-06-06 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024093040A Pending JP2024113134A (ja) 2017-01-27 2024-06-07 特定のｖｍａｔ２インヒビターを投与するための方法
JP2025126262A Pending JP2025146959A (ja) 2017-01-27 2025-07-29 特定のｖｍａｔ２インヒビターを投与するための方法

Family Applications After (15)

Application Number Title Priority Date Filing Date
JP2019540568A Active JP7199360B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2019540570A Active JP7199361B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2019540557A Active JP7199359B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2019540650A Active JP7107950B2 (ja) 2017-01-27 2017-10-10 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022008580A Withdrawn JP2022040408A (ja) 2017-01-27 2022-01-24 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022113075A Withdrawn JP2022137219A (ja) 2017-01-27 2022-07-14 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022160177A Withdrawn JP2022174343A (ja) 2017-01-27 2022-10-04 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022160833A Withdrawn JP2022174345A (ja) 2017-01-27 2022-10-05 特定のｖｍａｔ２インヒビターを投与するための方法
JP2022160831A Withdrawn JP2022174344A (ja) 2017-01-27 2022-10-05 特定のｖｍａｔ２インヒビターを投与するための方法
JP2023149999A Pending JP2023161033A (ja) 2017-01-27 2023-09-15 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024092155A Pending JP2024107169A (ja) 2017-01-27 2024-06-06 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024092148A Pending JP2024107167A (ja) 2017-01-27 2024-06-06 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024092152A Pending JP2024107168A (ja) 2017-01-27 2024-06-06 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024093040A Pending JP2024113134A (ja) 2017-01-27 2024-06-07 特定のｖｍａｔ２インヒビターを投与するための方法
JP2025126262A Pending JP2025146959A (ja) 2017-01-27 2025-07-29 特定のｖｍａｔ２インヒビターを投与するための方法

Country Status (12)

Country Link
US (9) US10874648B2 (enExample)
JP (16) JP7090151B2 (enExample)
KR (14) KR20190108149A (enExample)
CN (6) CN116712434A (enExample)
AU (7) AU2017395702B2 (enExample)
CA (5) CA3051832C (enExample)
EA (5) EA201991780A1 (enExample)
MX (6) MX394417B (enExample)
MY (5) MY202219A (enExample)
PH (6) PH12022553251A1 (enExample)
SG (3) SG11201906883SA (enExample)
WO (5) WO2018140095A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3875459T (lt) 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
US20200345663A1 (en) * 2018-06-10 2020-11-05 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
SG11202100303QA (en) * 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
JOP20210274A1 (ar) * 2019-05-09 2023-01-30 Neurocrine Biosciences Inc طرق لإعطاء مثبط vmat2 معين
TW202114676A (zh) * 2019-08-14 2021-04-16 瑞士商Ｆ 賀夫曼 賀許公司 治療癌症之方法
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP4076463A1 (en) * 2019-12-20 2022-10-26 Eisai R&D Management Co., Ltd. Use of lemborexant for treating insomnia
JP2024524324A (ja) 2021-06-30 2024-07-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症のアドオン処置において使用するためのバルベナジン
EP4362942A1 (en) 2021-06-30 2024-05-08 Neurocrine Biosciences, Inc. Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
MX2024000841A (es) * 2021-08-16 2024-05-10 Foresee Pharmaceuticals Co Ltd Composiciones depot de polimeros para el suministro de liberacion sostenida de inhibidores de vmat2.
US20250064990A1 (en) 2021-08-20 2025-02-27 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors
EP4398893A4 (en) * 2021-09-10 2025-07-16 ATAI Life Sciences AG IBOGAINE COMBINATION THERAPY
EP4422603A1 (en) * 2021-10-29 2024-09-04 Neurocrine Biosciences, Inc. Valbenazine compositions
AU2023232134A1 (en) 2022-03-07 2024-10-03 Neurocrine Biosciences, Inc. Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
US20240156723A1 (en) * 2022-11-16 2024-05-16 Foresee Pharmaceuticals Co., Ltd. Depot compositions for vesicular monoamine transporter 2 (vmat2) inhbitors
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108645A1 (en) 2004-02-11 2008-05-08 Cambridge Laboratories, (Ireland), Ltd. Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them
JP2010509366A (ja) 2006-11-08 2010-03-25 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法
JP2016506957A (ja) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｖｍａｔ２のベンゾキノロン阻害剤
US20160346270A1 (en) 2014-01-27 2016-12-01 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2016210180A2 (en) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1068938A (en) 1910-11-07 1913-07-29 Gustav F Schulze Vehicle-apron.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5283918A (en) 1976-01-01 1977-07-13 Wellcome Found Pharmaceutical composition
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
JPS57209225A (en) 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
JPS6028987A (ja) 1983-07-28 1985-02-14 Chugai Pharmaceut Co Ltd 新規ジゴキシン誘導体
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DK0946169T3 (da) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1313473A2 (en) 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
CA2487732C (en) 2002-05-28 2013-10-15 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
AU2003272608A1 (en) 2002-09-19 2004-04-08 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
US7230097B2 (en) 2003-03-10 2007-06-12 Lupin Ltd. Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid
GB0307259D0 (en) 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
ATE415973T1 (de) 2004-10-28 2008-12-15 Wyeth Corp Gemeinsame gabe von tigecyclin und digoxin
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
US20110257220A1 (en) 2005-08-06 2011-10-20 Cambridge Laboratories (Ireland) Limited 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses
US20100076087A1 (en) 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
GB0721669D0 (en) 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
US20100096319A1 (en) 2008-10-17 2010-04-22 General Electric Company Separator assembly
EP3354753B1 (en) * 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012153341A1 (en) 2011-05-12 2012-11-15 Arch Pharmalabs Limited A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
CN110200958A (zh) * 2012-12-18 2019-09-06 万达制药公司 昼夜节律紊乱的治疗
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CN106061506A (zh) 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
KR20220140647A (ko) 2014-05-06 2022-10-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
MX375718B (es) 2015-02-06 2025-03-06 Neurocrine Biosciences Inc [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
IL288712B2 (en) 2015-03-06 2024-01-01 Auspex Pharmaceuticals Inc Methods for the treatment of abnormal involuntary movement disorders
LT3875459T (lt) 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
JP2020500875A (ja) 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
CN110691596A (zh) 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
JP2020512986A (ja) 2017-04-01 2020-04-30 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
EP4082546A1 (en) * 2017-05-16 2022-11-02 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US10857144B2 (en) * 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
KR102776189B1 (ko) 2017-11-22 2025-03-04 아시아 케미컬 인더스트리스 리미티드 발베나진의 고상 형태
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
JOP20210274A1 (ar) 2019-05-09 2023-01-30 Neurocrine Biosciences Inc طرق لإعطاء مثبط vmat2 معين
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108645A1 (en) 2004-02-11 2008-05-08 Cambridge Laboratories, (Ireland), Ltd. Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them
JP2010509366A (ja) 2006-11-08 2010-03-25 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法
JP2016506957A (ja) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｖｍａｔ２のベンゾキノロン阻害剤
US20160346270A1 (en) 2014-01-27 2016-12-01 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2016210180A2 (en) 2015-06-23 2016-12-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Safety and Tolerability of Valbenazine(NBI-98854) in Subjcts with Tardive Dyskinesia: Results of Long-Term Exposure Data From Three Studies，Neuropsychopharmacology，2016年12月05日，Vol.41，S212-S213

Also Published As

Publication number Publication date
JP2020514318A (ja) 2020-05-21
JP2024113134A (ja) 2024-08-21
JP2022174344A (ja) 2022-11-22
AU2017395701B2 (en) 2024-02-15
AU2017395700A1 (en) 2019-08-22
PH12020550238A1 (en) 2021-02-15
CA3051830A1 (en) 2018-08-02
JP2022040408A (ja) 2022-03-10
AU2017395704B2 (en) 2022-02-24
MX2022007141A (es) 2022-07-19
AU2017395704B8 (en) 2022-03-17
CN110740731A (zh) 2020-01-31
EA201991782A1 (ru) 2021-09-23
WO2018140095A2 (en) 2018-08-02
CA3051832A1 (en) 2018-08-02
MY195934A (en) 2023-02-27
US10874648B2 (en) 2020-12-29
KR20250020723A (ko) 2025-02-11
AU2017395704A1 (en) 2019-08-22
KR20250078629A (ko) 2025-06-02
US20200268724A1 (en) 2020-08-27
JP7107950B2 (ja) 2022-07-27
KR20190108147A (ko) 2019-09-23
AU2017395702A1 (en) 2019-08-22
KR20190108149A (ko) 2019-09-23
KR20230038601A (ko) 2023-03-20
SG11201906885TA (en) 2019-08-27
US11040029B2 (en) 2021-06-22
CA3051834A1 (en) 2018-08-02
MX2019008853A (es) 2019-09-11
AU2017395702B2 (en) 2021-09-09
JP2022174343A (ja) 2022-11-22
EA201991780A1 (ru) 2021-10-26
US10912771B1 (en) 2021-02-09
MX393077B (es) 2025-03-24
CN111655034A (zh) 2020-09-11
JP2024107167A (ja) 2024-08-08
US20200338066A1 (en) 2020-10-29
JP7199360B2 (ja) 2023-01-05
EA202090676A1 (ru) 2021-10-08
JP2025146959A (ja) 2025-10-03
CA3078719A1 (en) 2018-08-02
US10952997B2 (en) 2021-03-23
CN116712434A (zh) 2023-09-08
KR20200066662A (ko) 2020-06-10
MX394415B (es) 2025-03-24
MY199695A (en) 2023-11-18
MY202219A (en) 2024-04-17
CN110740732A (zh) 2020-01-31
US20210169862A1 (en) 2021-06-10
WO2018140092A1 (en) 2018-08-02
US11439629B2 (en) 2022-09-13
JP2020505407A (ja) 2020-02-20
PH12019501734A1 (en) 2020-07-06
PH12019501744A1 (en) 2019-09-30
AU2017395703A1 (en) 2019-08-22
US20200268725A1 (en) 2020-08-27
JP2020514317A (ja) 2020-05-21
AU2022203201A1 (en) 2022-06-02
US20200093808A1 (en) 2020-03-26
EA201991786A1 (ru) 2020-01-16
JP2020536905A (ja) 2020-12-17
AU2017395704A8 (en) 2022-03-17
US20190381016A1 (en) 2019-12-19
US20210030742A1 (en) 2021-02-04
KR20250022883A (ko) 2025-02-17
KR20230169457A (ko) 2023-12-15
KR20230170135A (ko) 2023-12-18
CA3051829A1 (en) 2018-08-02
JP2022137219A (ja) 2022-09-21
MX394418B (es) 2025-03-24
MX2019008855A (es) 2019-09-11
US20210046060A1 (en) 2021-02-18
MY191077A (en) 2022-05-30
MY203491A (en) 2024-06-30
KR20190108146A (ko) 2019-09-23
WO2018140093A1 (en) 2018-08-02
KR20250020722A (ko) 2025-02-11
JP2022174345A (ja) 2022-11-22
CA3051832C (en) 2024-05-28
MX2019008868A (es) 2019-09-16
US10857137B2 (en) 2020-12-08
SG11201906883SA (en) 2019-08-27
KR20200126430A (ko) 2020-11-06
JP2024107169A (ja) 2024-08-08
JP2024107168A (ja) 2024-08-08
AU2022203201B2 (en) 2023-11-02
WO2018140095A3 (en) 2018-11-29
MX394417B (es) 2025-03-24
KR20230170136A (ko) 2023-12-18
PH12019501740A1 (en) 2019-10-07
AU2017395703B2 (en) 2021-09-23
MX2019008854A (es) 2019-09-11
AU2022203327A1 (en) 2022-06-09
JP7199361B2 (ja) 2023-01-05
PH12019501732A1 (en) 2020-03-16
AU2017395700B2 (en) 2022-02-24
AU2017395701A1 (en) 2020-06-18
CN110769826A (zh) 2020-02-07
KR20190108148A (ko) 2019-09-23
MX2020003462A (es) 2020-08-03
EA201991784A1 (ru) 2021-09-23
WO2018140094A1 (en) 2018-08-02
WO2018140096A1 (en) 2018-08-02
PH12022553251A1 (en) 2024-05-20
CN110709071A (zh) 2020-01-17
JP7199359B2 (ja) 2023-01-05
CA3051834C (en) 2024-05-28
JP2023161033A (ja) 2023-11-02
US20200268743A1 (en) 2020-08-27
JP2020505408A (ja) 2020-02-20
SG11201906891RA (en) 2019-08-27

Similar Documents

Publication Publication Date Title
JP7090151B2 (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
JP2021193146A (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
US10993941B2 (en) Methods for the administration of certain VMAT2 inhibitors
JP2021528386A (ja) Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法
HK40016560A (en) Methods for the administration of certain vmat2 inhibitors
HK40039894A (en) Methods for the administration of certain vmat2 inhibitors

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20200605

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20200605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220613

R150 Certificate of patent or registration of utility model

Ref document number: 7090151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250